ACADIA Pharmaceuticals Inc. (ACAD)

Market Cap	3.70B +0.4%
Revenue (ttm)	1.10B +9.9%
Net Income	375.65M +64.1%
EPS	2.20 +60.4%
Shares Out	171.24M
PE Ratio	9.87
Forward PE	39.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	344,868
Open	21.72
Previous Close	21.43
Day's Range	21.48 - 21.85
52-Week Range	19.69 - 28.35
Beta	0.83
Analysts	Buy
Price Target	31.65 (+46.66%)
Earnings Date	May 6, 2026

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting sy...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 27, 2004
• Employees: 798
• Stock Exchange: NASDAQ
• Ticker Symbol: ACAD
• Website: https://www.acadia.com

Financial Performance

In 2025, ACADIA Pharmaceuticals's revenue was $1.07 billion, an increase of 11.87% compared to the previous year's $957.80 million. Earnings were $391.00 million, an increase of 72.66%.

Analyst Summary

According to 21 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price target is $31.65, which is an increase of 46.66% from the latest price.

Price Target

$31.65

(46.66% upside)

Analyst Consensus: Buy